Pharmacokinetics of cisplatin in analbuminemic rats

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 9, 1999, Pages 421-428

  Takada, Kanji ^a   Kawamura, Tomonori ^a   Inai, Maya ^a   Masuda, Satoru ^a   Oka, Takashi ^a   Yoshikawa, Yukako ^a   Shibata, Nobuhito ^a   Yoshikawa, Hiroshi ^b   Ike, Osamu ^c   Wada, Hiromi ^c   Hitomi, Shigeki ^c  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Albumin; Analbuminemic rat; Cisplatin; Pharmacokinetics; Protein binding

Indexed keywords

ALBUMIN; CISPLATIN; IMMUNOGLOBULIN; OROSOMUCOID;

ANALBUMINEMIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG CLEARANCE; DRUG PROTEIN BINDING; MALE; NONHUMAN; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 0033851632     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-081X(199912)20:9<421::AID-BDD206>3.0.CO;2-9     Document Type: Article

References (30)

1. Cisplatin: The future
2. High-dose cisplatin in advanced head and neck cancer
3. The measurement of cisDDP-DNA adduct levels in testicular cancer patients
4. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients
5. Cisplatin effects on F-actin and matrix proteins precede renal tubular cell detachment and apoptosis in vitro
6. Preparation and metabolism of a cisplatin/serum protein complex
7. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion
8. Pharmacokinetics of cisplatin and its monohydrated complex in humans
9. The renal clearance of unconjugated cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats
10. Low-dose continuous administration of cisplatin for the postoperative chemotherapy of lung cancer
11. Influence of renal disease on pharmacokinetics
12. Irreversible binding of cisplatin in rat serum
13. Disposition of warfarin in analbuminemic rats
14. Disposition of phenytoin in analbuminemic rats
15. Oral sustained-release CDDP capsule
16. Development and evaluation of noncompartmental pharmacokinetic analysis program 'WinHARMONY' using Visual BASIC language having a function of an automatic recognition of terminal elimination phase of plasma drug concentration vs. time profile
17. Relationship between the exposure to cisplstin, DNA-adduct formation in leukocytes and tumor response in patients with solid tumors
18. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity
19. Pharmacokinetics of cisplatin in combined cicplatin and 5-fluorouracil therapy: A comparative study of three different schedules of cicplatin administration
20. Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats
21. Albumin-deficient rat mutant
22. In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex
23. Clinical and pharmacological studies with cis-diamminedichloroplatium(II)
24. The antimalarial drug halofantrine is bound to low and high density lipoproteins in human serum
25. cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: A pharmacokinetic approach
26. Cisplatin binding sites on human albumin
27. Reversible and irreversible interactions of a cisplatin analog bearing a 1,2-diphenylethylenediamine ligand with plasma and plasma proteins in vitro